[E-Daily Reporter NA EUN-KYUNG ] Boil-like lumps repeatedly form and burst in areas such as the armpits and groin. Pus, oozing, and pain persist, and if the condition worsens, drainage tracts (channels connecting lesions beneath the skin through which pus flows) and scars remain. This is hidradenitis suppurativa, a condition that makes even walking or getting dressed a painful ordeal. A meta-analysis published last year in the international academic journal *Journal of the American Academy of Dermatology* estimated the global prevalence at 0.99 percent—meaning approximately one in every 100 people suffers from it.
The suffering does not stop at the skin. A meta-analysis on skin diseases published last year also found that patients with hidradenitis suppurativa have a higher risk of suicide than the control group. This underscores the immense psychological burden this disease places on patients.
A South Korean company that has taken on the challenge of treating this disease is #IMBiologics Corp. Founded in 2020, it listed on the KOSDAQ market on March 20 of this year. Recognized for the potential of its antibodies against autoimmune diseases, the company licensed its IMB-101 and IMB-102 technologies to Navigator Medicine, a U.S.-based new drug development specialist under the Newcoin umbrella. Subsequently, the total contract value—which includes Asian rights—amounts to $1.262 billion, or approximately 1.8 trillion won, including milestone payments.
Research results presented at the European Academy of Dermatology and Venereology (EADV) 2026 regarding the potential of a dual OX40L and TNF blockade strategy for treating suppurative hidradenitis. The image on the left shows a histological study by researchers at Bin Medical University confirming the distribution of the two targets around the patient’s drainage tract, while the images in the center and on the right present the results of Sanofi’s Phase 2a clinical trial for Brivekymic, a competitive drug with the same mechanism of action. (Source: IMBiologics Corp.)
Will it
overcome the limitations of single-target therapies?…Simultaneous Blockade of Immune and Inflammatory Signals
Hidradenitis suppurativa, a type of autoimmune disease, is not a condition without treatment options. In addition to antibiotics and surgery, biologics such as adalimumab, secukinumab, and bimekizumab are also used. However, many patients do not achieve sufficient therapeutic response. In two Phase 3 clinical trials of adalimumab—one of the standard treatments for moderate-to-severe hidradenitis suppurativa—the proportion of patients who experienced a reduction of more than half in the number of abscesses and inflammatory nodules by week 12, and in whom the number of abscesses and drainage tracts did not increase, was only 41.8% and 58.9%, respectively. This means that 4 to 6 out of every 10 patients failed to meet the treatment response criteria.
IMBiologics Corp. is seeking a breakthrough with IMB-101, a bispecific antibody that simultaneously blocks OX40L—which is involved in immune cell activation—and tumor necrosis factor (TNF), a mediator of inflammation. An official from IMBiologics Corp. explained the strengths of IMB-101, stating, “Since autoimmune diseases involve the complex interaction of various immune and inflammatory signals, it may be difficult to achieve sufficient therapeutic effects by inhibiting a single target alone.”
Recently, at the European Academy of Dermatology and Venereology (EADV) conference, researchers from the Medical University of Vienna in Austria, supported by Navigator Medicine, presented the results of their analysis of lesion tissue from patients with hidradenitis suppurativa. OX40L- and TNF-positive cells were observed together around cells associated with drainage tracts, thereby strengthening the scientific basis for a therapeutic strategy that simultaneously blocks both targets. In the Phase 1 clinical trial of NAV-240 (IMB-101) conducted on healthy participants, favorable safety and tolerability, low immunogenicity, and the maintenance of antiviral T-cell function were confirmed.
An IMBioLogics Corp. official explained, “We have demonstrated the scientific feasibility of an approach that simultaneously targets OX40L and TNF in chronic lesions, including drainage tunnels,” adding, “We plan to confirm the actual clinical efficacy through a Phase 2a clinical trial involving patients.”
Next year is a key milestone. Navigator plans to release the results of the global Phase 2a clinical trial for NAV-240 in the third quarter of next year. The strategy is to first confirm the drug’s safety and therapeutic efficacy in actual patients via intravenous injection.
Navigator also has NAV-242, a follow-up candidate optimized from NAV-240 to extend its half-life and enable subcutaneous (SC) administration. The goal for NAV-242 is to maintain the dual OX40L and TNF blockade mechanism while designing the drug to remain in the body longer, thereby extending the dosing interval. Full Phase 1 clinical trial results are expected in the second half of next year.
Among competing drugs in the global market targeting the same two targets, Sanofi’s Brivekymic is at a more advanced stage of development. Like NAV-240, it simultaneously blocks OX40L and TNF, but differs structurally in that it utilizes nanobodies—antibody fragments smaller than conventional antibodies. After confirming a signal of efficacy in a Phase 2a clinical trial for hidradenitis suppurativa, it is currently undergoing a Phase 2b trial to evaluate efficacy and safety across different dose levels.
An official from IMBiologics Corp. stated, “While Sanofi’s Brivekimic was tested in clinical trials with a dosing schedule of once every two weeks, NAV-242 aims for a longer dosing interval,” adding, “If we can reduce the frequency of administration while maintaining sufficient efficacy and safety, this could become a key competitive advantage in improving patient convenience for autoimmune diseases requiring long-term treatment.”
Comparison of development characteristics between IMB-101 from IMBiologics Corp. and Sanofi’s Brivekemic, a competing drug targeting the same target. NAV-240, an IMB-101-based intravenous candidate, is currently undergoing a Phase 2a clinical trial for hidradenitis suppurativa, while NAV-242, a follow-up subcutaneous injection candidate with an extended half-life, is being developed with the goal of administration at 8- to 12-week intervals. The safety and immunogenicity data are from different trials. (Source: IMBiologics Corp.)
Development of Follow-on Immunomodulatory Antibodies… Pursuing Technology Export Before Clinical Trials
IMBiologics Corp. plans to leverage the experience gained from IMB-101 in its follow-up development efforts. IMB-105, which targets a new, higher-order immunoregulatory pathway, aims to become the first-in-class therapy that suppresses excessive T-cell activation and restores immune balance. On the 2nd, the company signed a Material Transfer Agreement (MTA) with GCGreen Cross Corporation(006280)to evaluate the potential for developing a new bispecific antibody.
IMB-106, which reduces pathogenic autoantibodies, is another follow-up commercialization project. Based on efficacy and pharmacokinetic data from monkey models, the company is pursuing technology exports at the preclinical stage. Since it is difficult to predict the efficacy of treatments for autoimmune diseases based solely on mouse experiments due to differences between the immune systems of animals and humans, the company places great importance on data obtained from primates, which are relatively similar to humans. This is why IMBiologics Corp. insists on conducting monkey experiments, despite the high costs involved.
An IMBiologics Corp. official stated, “During the development of IMB-101, we accumulated comprehensive R&D capabilities ranging from antibody design and optimization to preclinical and clinical development,” adding, “We are also actively exploring new immunomodulatory mechanisms and dual-target strategies for our subsequent pipeline.”
The company plans to conduct commercialization discussions in parallel starting from the candidate selection stage. The official said, “We plan to proactively expand various business development opportunities, such as technology transfer and joint development, starting from the candidate selection stage.”
Although the stock price remains below the initial public offering (IPO) price, the company maintains that this is not due to fundamental issues and remains optimistic about a rebound. IMBiologics Corp. went public at an IPO price of 26,000 won and rose to 104,000 won on its first trading day, but its closing price on the 17th was 12,200 won—an 88.3% drop from its peak.
An IMBiologics Corp. official emphasized, “Immediately after the listing, we faced a confluence of factors: political instability in the Middle East, a shift in market demand toward the semiconductor sector, and continued selling by existing institutional shareholders.” The official added, “The selling by existing institutional shareholders, which had weighed on the stock price, has largely subsided. As we accumulate key data from the IMB-101 clinical proof-of-concept trial and subsequent candidate compounds, we expect the level of technological validation and interest in our company to increase further.”
InBody Co., Ltd.(041830)reported that its operating profit for the third quarter of this year nearly doubled year-over-year; however, its recurring operating profit—excluding one-time accounting effec…
GS Retail(007070)has supported domestic small and medium-sized partner companies in Vietnam in expanding their overseas sales channels, resulting in export consultation deals totaling approximately $1…
Boil-like lumps repeatedly form and burst in areas such as the armpits and groin. Pus, oozing, and pain persist, and if the condition worsens, drainage tracts (channels connecting lesions beneath the …